Cannapharmarx Stock Performance
| CPMD Stock | USD 0 0 42.86% |
The firm shows a Beta (market volatility) of 2.26, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CannaPharmaRx will likely underperform. CannaPharmaRx right now shows a risk of 15.35%. Please confirm CannaPharmaRx total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to decide if CannaPharmaRx will be following its price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days CannaPharmaRx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, CannaPharmaRx is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 335 K | |
| Total Cashflows From Investing Activities | 533.1 K |
CannaPharmaRx |
CannaPharmaRx Relative Risk vs. Return Landscape
If you would invest 0.78 in CannaPharmaRx on December 2, 2024 and sell it today you would lose (0.38) from holding CannaPharmaRx or give up 48.72% of portfolio value over 90 days. CannaPharmaRx is currently generating 0.0465% in daily expected returns and assumes 15.3541% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than CannaPharmaRx, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CannaPharmaRx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CannaPharmaRx's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as CannaPharmaRx, and traders can use it to determine the average amount a CannaPharmaRx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.003
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CPMD |
Estimated Market Risk
| 15.35 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CannaPharmaRx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CannaPharmaRx by adding CannaPharmaRx to a well-diversified portfolio.
CannaPharmaRx Fundamentals Growth
CannaPharmaRx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CannaPharmaRx, and CannaPharmaRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CannaPharmaRx Pink Sheet performance.
| Return On Equity | -2.51 | |||
| Return On Asset | -0.26 | |||
| Current Valuation | 20.13 M | |||
| Shares Outstanding | 257.57 M | |||
| Price To Book | 11.05 X | |||
| EBITDA | (6.07 M) | |||
| Cash And Equivalents | 5.18 K | |||
| Total Debt | 14.96 M | |||
| Debt To Equity | 7.05 % | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (2.41 M) | |||
| Earnings Per Share | (0.12) X | |||
| Total Asset | 114.33 K | |||
| Retained Earnings | (28.64 M) | |||
| Current Asset | 233 K | |||
| Current Liabilities | 518 K | |||
About CannaPharmaRx Performance
By analyzing CannaPharmaRx's fundamental ratios, stakeholders can gain valuable insights into CannaPharmaRx's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CannaPharmaRx has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CannaPharmaRx has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CannaPharmaRX, Inc. operates in the cannabis industry in Canada. The company was incorporated in 1998 and is based in Calgary, Canada. Cannapharmarx operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about CannaPharmaRx performance evaluation
Checking the ongoing alerts about CannaPharmaRx for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CannaPharmaRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CannaPharmaRx had very high historical volatility over the last 90 days | |
| CannaPharmaRx has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (8.83 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CannaPharmaRx currently holds about 5.18 K in cash with (2.41 M) of positive cash flow from operations. |
- Analyzing CannaPharmaRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CannaPharmaRx's stock is overvalued or undervalued compared to its peers.
- Examining CannaPharmaRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CannaPharmaRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CannaPharmaRx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CannaPharmaRx's pink sheet. These opinions can provide insight into CannaPharmaRx's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CannaPharmaRx Pink Sheet analysis
When running CannaPharmaRx's price analysis, check to measure CannaPharmaRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CannaPharmaRx is operating at the current time. Most of CannaPharmaRx's value examination focuses on studying past and present price action to predict the probability of CannaPharmaRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CannaPharmaRx's price. Additionally, you may evaluate how the addition of CannaPharmaRx to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |